Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24756054 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPTRAD51KMT2AKDM4E | |
| SCHEMBL15890217 | 0.80 | NAMPT (0.56) | ALDH1A1RETNAMPT | |
| SCHEMBL30370027 | 0.79 | MCHR1 (0.67) | RETKMT2AKDM4EMEN1GFER | |
| SCHEMBL31600774 | 0.77 | ALDH1A1 (0.54) | ALDH1A1MAPTRAD51KMT2AKDM4E | |
| SCHEMBL31600350 | 0.77 | NPC1 (0.45) | ALDH1A1MAPTRAD51KMT2AKDM4E | |
| SCHEMBL20595896 | 0.77 | RORC (0.51) | RETMCHR1NAMPTMAOB | |
| SCHEMBL8063648 | 0.75 | ALDH1A1 (0.82) | ALDH1A1MAPTRAD51KMT2AKDM4E | |
| SCHEMBL15376568 | 0.75 | MCHR1 (0.54) | ALDH1A1RETKMT2AMEN1MCHR1 | |
| SCHEMBL2397057 | 0.74 | PIK3CD (0.46) | ALDH1A1MAPTRAD51KMT2AKDM4E | |
| SCHEMBL15377190 | 0.74 | MCHR1 (0.63) | RETKDM4ETDP1MCHR1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901111-B2 | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| US-8901111-B2 | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| US-8901111-B2 | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| WO-2014111871-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-24 | — | — | WO | disclosed |
| US-20120088741-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088741-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088741-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | US | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141817-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141809-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, DBH | ALDH1A1 709/4885MAPT 1489/4885RAD51 2062/4885 |
| US-20120088741-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, APEH | ALDH1A1 895/4885MAPT 1165/4885RAD51 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.